Becton Dickinson and Co vs State Street Technology Select Sector SPDR ETF — how do they compare? Becton Dickinson and Co trades at $154.99 (market cap $41.51B), while State Street Technology Select Sector SPDR ETF trades at $181.67. The key difference: Becton Dickinson and Co pays a 2.79% dividend while State Street Technology Select Sector SPDR ETF pays none, and State Street Technology Select Sector SPDR ETF is trading nearer its 52-week high, Becton Dickinson and Co nearer its low. Which is the better fit depends on your goals.
| BDX | XLK | |
|---|---|---|
Market Cap | $41.51B | — |
Sector | Health | Sector/Thematic |
52-Week High | $185.39 | $198.21 |
52-Week Low | $135.49 | $127.49 |
Enterprise Value | $57.97B | — |
Dividend Yield | 2.79% | — |
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
XLK trades at $181.28, down 2.43% on the day, with technical indicators showing a bearish moving average trend but neutral oscillators. The ETF has delivered strong year-to-date performance, gaining 33% as of July 2, 2026 (ETF Trends), driven by technology sector leadership. Recent news highlights robust Q2 earnings expectations and institutional inflows into tech ETFs.
Outlook remains cautiously optimistic given sector momentum and earnings growth projections, though risks include market concentration and valuation concerns. The neutral technical signal suggests near-term consolidation, while fundamental strength in tech supports long-term potential.
Trailing returns across standard periods
Latest headlines on both assets
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →